Michael O'Sullivan

Michael O'Sullivan is a Clinical Senior Lecturer in Paediatrics at the UWA Medical School, The University of Western Australia. He maintains active clinical roles as Consultant Immunologist at Fiona Stanley Hospital (since 2015), PathWest Laboratory Medicine WA (since 2013), and Perth Children's Hospital (since 2013), bridging academic research with clinical practice in pediatric immunology.

Dr. O'Sullivan's research focuses on food allergy treatment and prevention, with particular expertise in peanut allergy and oral immunotherapy. His work examines predictive biomarkers for treatment success, optimal dosing protocols, and long-term outcomes. Additional research interests include pertussis vaccination impacts on infant immunity and the role of microbiome in allergy development. His fingerprint analysis reveals strong specialization in Immunotherapy (100%), Peanut research (86%), Food Allergy (77%), and Peanut Allergy (69%).

His recent publications demonstrate a clear trajectory toward understanding predictors of successful peanut allergy treatment and optimizing immunotherapy protocols. The most recent articles (2024-2025) focus on IgE biomarkers, pertussis vaccine interactions, and emollient therapy in preterm infants, showing both depth in his core specialty and breadth across related immunological fields.

Dr. O'Sullivan has secured research funding including the FHRI COVID-19 VIP project (2021-2023) with the Western Australian Department of Health, where he served as Investigator 05. His work has generated 853 citations with an h-index of 16, indicating significant impact in his field.

His clinical work spans multiple major Western Australian hospitals, providing a robust platform for translational research that directly informs pediatric allergy treatment practices. This multi-institutional involvement facilitates large-scale clinical studies and broad implementation of research findings into clinical practice.